]>
IRCT20111105008013N2 IRCT 2018-08-26 Ahvaz University of Medical Sciences effect liqurice in treatment of schizophernia Effect of licorice (Glycyrrhiza glabra) versus placebo on increasing the efficiency of antipsychotics in women with chronic schizophrenia, a double-blind clinical trials 2018-01-21 anticipated 40 Complete https://irct.ir/trial/31394 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, the permuted block randomization will be used with quadruple blocks. blocks will be produced by using the online site (www.sealedenvelope.com), Blinding description: Unique codes, which is generated by the software, will be used on the drug boxes. By entering each individual into the study based on the produced sequence, the drug box in which the code is registered, will be assigned to the individual. During the research, the randomization list is held by the statistic consultant, and the participants, the project implementer and all those who participate in the measurement of the indicators will not be aware of the assigned groups. 2-3 schizophrenia. Intervention 1: Intervention group: one tablet of D-Reglis (IRAN DAROUK Co., Tehran, Iran) containing 380 mg of standardized dried licorice extract for 8 weeks and three times a day. Intervention 2: Intervention group: Placebo (starch + sugar) for 8 weeks and three times a day. Yes - There is a plan to make this available What will be shared: Only a part of the data will be shared When: The access period will be 6 months after the publication of the results To whom: The obtained data from current study will be available only for researchers working in academic and scientific institutions. Conditions: Six months after the publication of this study papers, the obtained data will be available to the applicant researchers for further analysis Where to obtain: Applicants can be contacted with corresponding author by e-mail How to obtain: Applicants will be able to access the obtained data from current study by sending an email to the corresponding author up to one month Comments:
public Amir Siahpoosh
Golestan road
Ahvaz Iran (Islamic Republic of) 6135733184 +98 61 3334 2197 siahpoosh-a@ajums.ac.ir Ahvaz University of Medical Sciences scientific Amir Siahpoosh
Golestan Road
Ahvaz Iran (Islamic Republic of) 6135733184 +98 61 3334 2197 siahpoosh-a@ajums.ac.ir Ahvaz University of Medical Sciences Iran (Islamic Republic of) Active schizophrenia Met DSM-IV criteria for chronic schizophrenia Drug regimen of risperidone (6 mg/day), cetirizine (4 mg/day) 18 years 60 years Female Bipolar disorder Borderline-schizotypal-Antisocial personality disorder ٍEating disorder Alcohol and drug (other than schizophrenia drugs) abuse in the past month Suicide or suicidal ideation History of neurologic and systemic disorders Thyroid dysfunction Administration of antidepressants and Anti-anxiety drugs Steroids (such as oral contraceptives) Use of MAO-I drugs Pregnancy and lactation F20 Schizophrenia Treatment - Drugs Treatment - Drugs Intervention group: one tablet of D-Reglis (IRAN DAROUK Co., Tehran, Iran) containing 380 mg of standardized dried licorice extract for 8 weeks and three times a day Intervention group: Placebo (starch + sugar) for 8 weeks and three times a day Positive symptoms; Negative symptoms; General psychopathological symptoms. Timepoint: Start intervention and a month later. Method of measurement: PANSS score. Ahvaz University of Medical Sciences Approved 2012-01-21 Ahvaz Jundishapur University of Medical Sciences Golestan Road Ahvaz Khouzestan Iran (Islamic Republic of)